Hostname: page-component-7dd5485656-glrdx Total loading time: 0 Render date: 2025-10-28T03:11:21.686Z Has data issue: false hasContentIssue false

Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis: commentary, de Leon

Published online by Cambridge University Press:  09 October 2025

Jose de Leon*
Affiliation:
Mental Health Research Center, Eastern State Hospital, Lexington, USA Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apóstol Hospital, University of the Basque Country, Vitoria, Spain
*
Correspondence: Jose de Leon. Email: jdeleon@uky.edu

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Commentary
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Wagner, E, Korman, N, Solmi, M, Mortazavi, M, Aminifarsani, Z, Dubrovin Leão, D, et al. Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis. Br J Psychiatry [Epub ahead of print] 2 June 2025. Available from: https://doi.org/10.1192/bjp.2025.89.CrossRefGoogle Scholar
de Leon, J. Can slow personalized titration using c-reactive protein monitoring decrease the high rates and mortality of clozapine-associated myocarditis seen in some countries? A call for research. J Clin Psychopharmacol 2024; 44: 212–9.10.1097/JCP.0000000000001843CrossRefGoogle ScholarPubMed
Rohde, C, Polcwiartek, C, Kragholm, K, Ebdrup, BH, Siskind, D, Nielsen, J. Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study. Acta Psychiatr Scand 2018; 137: 4753.CrossRefGoogle ScholarPubMed
Tirupati, S, Arachchi, MK. High rates of myocarditis with clozapine in the Hunter region of Australia. Schizophr Res 2024; 264: 543–8.10.1016/j.schres.2024.01.030CrossRefGoogle ScholarPubMed
Farooq, S. Ethnicity and clozapine metabolism. Br J Psychiatry 1998; 173: 87.10.1192/bjp.173.1.87aCrossRefGoogle ScholarPubMed
Rostami-Hodjegan, A, Amin, AM, Spencer, EP, Lennard, MS, Tucker, GT, Flanagan, RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24: 70–8.CrossRefGoogle ScholarPubMed
Reeves, S, Bertrand, J, Obee, SJ, Hunter, S, Howard, R, Flanagan, RJ. A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status. Br J Clin Pharmacol 2024; 90: 135–45.10.1111/bcp.15691CrossRefGoogle ScholarPubMed
de Leon, J. Reflections on the complex history of the concept of clozapine-induced inflammation during titration. Psychiatr Danub 2022; 34: 411–21.10.24869/psyd.2022.411CrossRefGoogle ScholarPubMed
Partanen, JJ, Häppölä, P, Kämpe, A, Ahola-Olli, A, Hellsten, A, Rask, SM, et al. High burden of ileus and pneumonia in clozapine-treated individuals with schizophrenia: a Finnish 25-year follow-up register study. Am J Psychiatry 2024; 181: 879–9.10.1176/appi.ajp.20230744CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.